3 completed. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
Follow Regulus Therapeutics Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease RGLS8429, Placebo - Autosomal Dominant Polycystic Kidney Disease, ADPKD | Phase 1 | Completed | Regulus Therapeutics Inc. | 68 | 2022-10-06 | 2025-06-03 |
| A Study of RGLS8429 in Healthy Volunteers RGLS8429, Placebo volume-matching RGLS8429 dose - Healthy Volunteers | Phase 1 | Completed | Regulus Therapeutics Inc. | 32 | 2022-06-10 | 2025-08-27 |
| A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney Disease RGLS4326 - Polycystic Kidney Disease, Autosomal Dominant | Phase 1 | Completed | Regulus Therapeutics Inc. | 19 | 2020-10-13 | 2021-12-15 |
Polycystic Kidney, Autosomal Dominant (3)
United States (3)
Rekha Garg, MD (2) · Karl Cremer, PharmD (1)
PMID 39331470, PMID 39356039, PMID 41385299, PMID 41643210, PMID 41701531